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1. INTRODUCTION 
Dendritic cells (DC) are antigen presenting cells of hemopoietic origin, uniquely 
well-equipped to activate naive T cells. 1 Evidence also exists however, for DC tolero-
genicity.2 During primary activation, mature T cells change from an activation-induced 
cell death (AICD) -resistant to an AICD-sensitive phenotype.3 The complete molecular 
basis for this transition remains to be determined, but CD95 (Fas/ Apo-l) and CD95L (Fas 
ligand; FasL) appear to play an important role in the homeostatic regulation of T cell re-
sponses.4 It seems that CD95L can mediate opposite effects (T cell activation or apop-
tosis) depending on the state of activation of the responding T cells. Previously, we have 
shown that mouse bone marrow (BM)-derived DC progenitors deficient in expression of 
cell surface costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are capable of in-
ducing alloantigen-specific T cell hyporesponsiveness$ and prolonging allograft survival.6 
Others have shown recently that a major subpopulation of freshly-isolated mouse lym-
phoid tissue DC is FasL\ and can induce apoptosis in allogeneic T cells.7 In the course of 
studies on DC propagated in vitro from mouse BM, we observed that these cells expressed 
Fas L. Our aim was to determine whether these cells could induce T cell apoptosis and 
whether costimulatory molecule expression could affect this activity. 
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2. MATERIALS AND METHODS 
2.1. Animals 
10-12-week-old male BIO.BRlSnJ (BR; H_2k), C57BLllOJ ( BIO, H_2b), C57BLl6J I 
(B6; H_2b) and B6.Smn.C3H-gld (B6.gld, H_2b; FasL-deficient) mice were purchased from I 
The Jackson Laboratory (Bar Harbor, ME). 
2.2. Propagation and Purification of BM-Derived DC ! 
I 
The DC were propagated from normal BIO.BR mouse BM in GM-CSF+IL-4 as de-I 
scribed.5•s They were purified over metrizamide (to approximately 90% purity; in some: 
experiments, DEC-20S+, B7-2+ DC (purity >95%) sorted using a FACStar® plus celli 
sorter (Becton Dickinson & Co, Mountain View, CA) were used.9 I 
2.3. Flow Cytometric Analysis of FasL Expression Using Fas-Fc Fusion 
Protein 
FasL expression on DC was analyzed by FACS. Metrizamide-purified BM DC were 
first incubated with 0.1 mg/ml mouse Ig (PharMingen, San Diego, CA), 1% v/v normal· 
goat serum (NGS; Vector Laboratories Inc., Burlingame, CA) and 50 J,1g/ml anti-FcR mAb 
2.4 G2 (PharMingen) for 10 min at 4°C to block Fe receptor binding. Mouse Fas-Fe fusion 
protein (Immune x Corporation, Seattle, W A) or purified human IgG was then added at 
SOJ,1g/ml and the cells incubated for 30 min. They were then washed and stained with anti-
human IgG-FITC (Caltag Laboratories, South San Francisco, CA) at the same concentra-
tion. 
2.4. Immunoperoxidase Staining for FasL 
Fas-Fc fusion protein was also used for staining of cytospins and was added 
(lOJ,1g/ml) to unfixed preparations of DC after incubation with 0.1 mg/ml mouse Ig, NGS 
(1%) and SO mg/ml anti-FeR mAb 2AG2 (Pharmingen) for 10 min at 4°C. peroxidaSe-\ 
conjugated mouse anti-human IgG was then added, and the Fas-Fc fusion protein local-
ized by the addition of chromogenic AEC substrate for S min. 
. I 
! 
i 2.5. Reverse Transcriptase peR and DNA Sequencing 
Total cellular RNA was extracted with TRlzol (Life Technologies, Gaithersburg,1 
MD) and 2 J,1g was used for cDNA synthesis using SuperScript II RT (Life Technologies)i 
and both Fas L and ~-actin primers. The FasL amplified product from the purified DCI 
cDNA was cloned into Bluescript II SK (Stratagene, La Jolla, CA) and sequenced with anI 
automated sequencer (Applied Biosystems Inc., Foster City, CA). 
2.6. Mixed Leukocyte Reactions (MLR) 
These were performed using nylon wool purified splenic T eells as responders, as; 
described previously in detai1. 10 . 
I 
! 
I 
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2.7. Costimulatory Molecule Blockade 
In some experiments, mouse CTLA4-Ig fusion protein (a gift from Dr. P.S. Linsley, 
Bristol-Myers-Squibb, Seattle, WA) or control human Ig was added at the start of the cell 
proliferation or DNA fragmentation assays. 
2.S. Radiometric Assay for DNA Fragmentation 
Splenic T cells activated either with Con A (31lg/m1; 48 h) or irradiated allogeneic 
spleen cells (1:1 ratio; 72 h) were labeled for 18 h with SIlCilml [3H] thymidine at 37°C in 
complete medium. The target cells (105) were then combined with various numbers of DC 
or spleen cells (as effectors) in a total volume of2001l1 per well in complete medium in 96 
well plates and incubated at 37°C for 4 - 18 h. Unfragmented labeled high molecular 
weight DNA was collected by filtration through glass fiber filters (Pharmacia) and 
counted in a liquid scintillation counter. Data are expressed as % DNA fragmentation = 
100 x (l-cpm in the presence of effector sic pm in the absence of effectors). 
2.9. Spectrofluorometric Assay for DNA Fragmentation 
The protocol was as described previously in detail by McCarthy et al. (11). 
2.10. In Situ Nick-End Labeling 
DNA strand breaks in fixed cytospin preparations were identified by in situ terminal 
deoxynucleotidyl transferase (TdT)-mediated (dUTP) nick end labeling (TUNEL) (12). 
3. RESULTS 
3.1. Culture, Purification, and Allostimulatory Activity of Bone 
Marrow (BM)-Derived DC 
The DC propagated in GM-CSF+IL-4 and purified as described in the Materials and Meth-
ods (DEC 205+; MHC class nhi, B7-2+[CD861, CD40+, CDllc) were highly efficient inducers of 
primary allogeneic T cell responses. Blockade of the B7-CD28 costimulatory pathway however, 
, by addition ofCTLA4-Ig at the start of cultures, significantly inhibited the MLR. 
3.2. FasL Expression on BM-Derived DC 
FasL expression was detected on DC by immunoperoxidase labeling, and by flow 
cytometric analysis using the mouse Fas-Fc fusion protein (Fig. 1). 
3.3. RT-PCR Analysis and cDNA Cloning 
The expression of message for Fas L in purified DC was confirmed by RT -PCR 
analysis. Levels of FasL mRNA in DC were similar to those expressed by Con A-acti-
vated T cells. The FasL amplified product from the DC cDNA was cloned into Bluescript 
II SK, sequenced and found to be identical to the mouse FasL sequence deposited in Gen-
Bank, Accession No. U06948. 
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Figure I. Immunofluorescence staining for FasL on in vitro generated DC using Fas-Fc fusion protein and de-
tected by flow cytometric analysis. 
3.4. Induction of DNA Fragmentation in Fas+ Jurkat T Cells and Its 
Inhibition by Fas-Fc Fusion Protein 
DC propagated from the BM of "wild-type" B6 mice but not those from g/d (FasL-
deficient) mice induced dose-related levels of DNA fragmentation. Similar data were ob-
tained using DC propagated from BIO.BR BM. Killing was partially blocked however, by 
the addition of Fas-Fc fusion protein at the start of the assay (data not shown). 
3.5. Induction of DNA Fragmentation in Activated T Cells and Its 
Enhancement by CTLA4-Ig 
Con A-stimulated syngeneic (BlO.BR) or allogeneic (BIO) T cell blasts or allo-acti-
vated T cells were labeled with eHJ thymidine and used as targets. Cultured DC or fresh 
bulk spleen cells from B IO.BR mice were also used as effectors. The DC induced only a 
low level of DNA fragmentation. DC from B IO.BR.BM induced similar levels of killing 
in BIO (allogeneic) or BIO.BR (syngeneic) Con A blasts, indicating that the induction of 
killing by DC was not MHC restricted. The extent of DNA fragmentation was equal to or 
higher than that achieved with fresh bulk splenic effector cells. When the DC were incu-
bated with T cells in the presence of CTLA4 - Ig, the effect was increased up to 4-fold. 
Similar results were obtained using alloactivated T cells as targets (Fig. 2). 
3.6. Death of Activated T Cells Induced by DC Is Mediated by the 
Fas/FasL Pathway 
The allostimulatory activity of DC from FasL-deficient mice was significantly 
higher and associated with lower DNA fragmentation of activated T cell targets compared 
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Figure 2. DNA fragmentation induced in alloactivated (BIO) T cells by normal (BR) mouse BM-derived DC in 
the absence or presence of CTLA4-lg. Addition of CTLA4-lg (200ng/ml) at the start of the cultures markedly in-
creased the death-inducing activity of the DC. Results are means :1: I SO and are representative of 3 separate ex-
\ periments. 
~ith DC from wild type B6 mice. However, increased levels of killing were induced by 
'gld DC when CTLA4-Ig was added to the cultures (Fig. 3). It appears therefore, that 
ras/FasL is not the only pathway by which DC can induce apoptosis of activated T cells. 
I 
! 
4. DISCUSSION 
This study shows for the first time, that co-stimulatory (B7) and death-signaling 
(FasL) molecules expressed on in vitro propagated DC play counter-regulatory roles in de-
termining activated T cell survival and proliferation. That the death-inducing capacity of 
the in vitro generated DC is linked to cell surface expression of FasL was shown by im-
munocytochemical techniques and by the capacity of Fas-Fc fusion protein to block T cell 
(illing by the DC. These observations are consistent with a recent report' that a major 
FasL + subpopulation of freshly-isolated mouse lymphoid tissue DC (CD8" FasL '") can in-
iuce apoptosis in activated T cells. In contrast to the DC studied by Siiss and Shortman,' 
lowever, the FasL + DC that we generated in vitro were CD8". Thus it appears that the 
tpoptosis-inducing activity of DC and the expression of CDS (also present on mouse 
'veto" cells [13]) are not strictly inter-related. Others have shown that monocytes/macro-
lhages. to which DC are related, and with which they may share a common precursor, can 
,romote apoptosis in activated T cells via expression of Fas L. 14•15 Thus, cultured M-CSF-
lerived macrophages induce selective depletion of allospecific T cells (15). An alterna-
ive/additional mechanism by which macrophages have been shown to inhibit T cell 
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Figure 3. DNA fragmentation in Con A blasts following 4h incubation with FasL-deficient (B6.gJd) DC in the ab-
sence or presence of CTLA4-Ig. Blockade of the B7-CD28 costimulatory pathway by CTLA4-lg was associated 
with increased T cell death. Results are means ± 1 SD and are representative of 2 separate experiments. 
proliferation/induce apoptosis is by the secretion of NO.9.16.17 NO may also be induced in 
DC by IFN-")" endotoxin or interaction with allogeneic T cells.9 
The Fas (APO-t; CD95) FasL system has emerged as an important pathway regulat-
ing the induction of T cell apoptosislS-20 and has been implicated in the deletion of graft-
infiltrating cells in immunologically privileged sites.21 Both Fas and FasL are induced on 
T cells upon activation, resulting in cell death by suicide or fratricide. In the present study, 
the expression of FasL on in vitro generated mouse DC was linked to the ability of these 
cells to induce low levels of killing in activated T cells. No T cell death significantly 
above background levels could be induced however. by DC propagated from FasL-defi-
cient (B6.g1d) mice. The capacity of CTLA4-Ig to markedly enhance the ability of potent, 
antigen-presenting DC to induce DNA fragmentation in T cells implicates a role for CD28 
costimulation in preventing T cell death. Others studying both human and mouse systems. 
have shown recently that CD28 costimulation enhances T cell survival following their ac-
tivation by TCR cross-linking. The resistance conferred by costimulation has been linked 
to increased expression of the survival gene bcl-xL within the T cells.!! 
Our finding that DC generated from BM of FasL-deficient mice can induce apop-
tosis in activated T cells in the presence of CTLA4-Ig suggests that Fas-independent path-
ways are also involved in DC-induced apoptosis. Indeed, it has also been shown that Fas 
is not necessary for activation-induced T cell death (23). We are investigating the expres-
sion of TNF family members23 on DC and in addition, the influence of other costimulatory 
pathways, such as CD40/CD40L and IL-12/IL-t2R on the resistance of activated T cells 
to apoptosis. 
The in vivo relevance of FasL expression on DC remains to be elucidated and such 
studies are clearly warranted. The potential of DC to induce death of activated T cells in 
the absence of costimulation may have key implications for interpretation of the docu-
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mented tolerogenic properties of DC. Since cells engineered to express FasL, have immu-
nosuppressive properties,24 the therapeutic potential ofFas L+ APC, in particular appropri-
ately "engineered" DC is worthy of evaluation. 
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